VC-backed Albynx debuts U.S. IPO
Ablynx, a Belgian biopharmaceutical company, has raised $200 million for its U.S. IPO after pricing its 11.4 million shares at $17.50 per share. The stock began trading October 25, 2017 on the NASDAQ under the ticker symbol “ABLX.” BofA Merrill Lynch, J.P. Morgan and Jefferies are the lead underwriters. According to Crunchbase, Ablynx’s backers include Abingworth, Alta Partners, Gimv and Sofinnova Partners.
25 October 2017•3 mins read
